BCIQ Profiles

Company Profile Report

Amgen considering risk-based Aimovig pricing

On a conference call to discuss 1Q18 earnings call, Amgen Inc. (NASDAQ:AMGN) EVP of Global Commercial Operation Anthony Hooper said the biopharma is "prepared to talk to payers

Read the full 281 word article

How to gain access

Continue reading with a
two-week free trial.